A Phase 1/2 interventional study of Verteporfin in Glioblastoma and Recurrent Glioblastoma, sponsored by Emory University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Emory University · Phase 1/2, Interventional, and Treatment
PI Decision
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Glioblastoma by Emory University — none open to participants now, 1 under way, none of them phase 3. Glioblastoma · Emory University.
Among the 12 studies in Glioblastoma by Emory University, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 1/2, and was the 8th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →None of the 12 studies in Glioblastoma by Emory University is open now. The open studies under Glioblastoma, anywhere →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6
First in 1995; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 12 across the 11 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
1 of the studies in Glioblastoma by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05798507Emory UniversityIdentification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | 2026-12-03 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Glioblastoma by Emory University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent).
Visudyne is FDA approved in combination with light to treat eye diseases. In this study we use Visudyne by itself like chemotherapy to kill tumor cells which may be sensitive to verteporfin.
PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability of successively higher doses of verteporfin (Visudyne [liposomal verteporfin]) and determine the maximum tolerated dose (MTD) in study participants with recurrent EGFR positive (+) glioblastoma (GBM). (Phase I) II. To evaluate the anti-tumor activity of Visudyne by assessing progression-free survival (PFS) and overall survival (OS). (Phase II) III. To describe the response rate of EGFR+ GBM in study participants treated with Visudyne. (Phase II)
SECONDARY OBJECTIVES:
I. To evaluate the anti-tumor activity of Visudyne by assessing progression-free survival (PFS) and overall survival (OS). (Phase I) II. To describe the response rate of EGFR+ GBM in study participants treated with Visudyne. (Phase I) III. To describe pharmacokinetics of Visudyne administered on a weekly schedule. (Phase I) IV. To evaluate the safety and tolerability of successively higher doses of Visudyne in study participants with recurrent EGFR+ GBM. (Phase II)
OUTLINE: This is a dose-escalation study.
Patients receive verteporfin intravenously (IV) over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days and then every 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Verteporfin
Given IV
Also known as: Benzoporphyrin Derivative Monoacid Ring A, BPD-MA, Visudyne
Incidence of Adverse Events (Phase I)
Will be graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For each adverse event, information to be collected includes event description, time of onset, clinician assessment of severity, relationship to study product (assessed only by those with the training and authority to make a diagnosis), and time of resolution/stabilization of the event.\[
Time frame: Safety follow-up is 30 days after the last drug administered (at Day 36 +/- 1 day) *see protocol[
11 participants recruited; 9 went on to receive protocol treatment.
| Milestone | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Started | 3 | 2 | 3 | 1 |
| Completed | 3 | 2 | 3 | 1 |
| Not completed | 0 | 0 | 0 | 0 |
Will be graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For each adverse event, information to be collected includes event description, time of onset, clinician assessment of severity, relationship to study product (assessed only by those with the training and authority to make a diagnosis), and time of resolution/stabilization of the event.\[
| Participants | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Any | 2 | 1 | 3 | 1 |
| Blood and lymphatic system disorders | 0 | 0 | 1 | 0 |
| Ear and labyrinth disorders | 0 | 0 | 1 | 0 |
| Gastrointestinal disorders | 0 | 0 | 1 | 1 |
| General disorders and administration site conditions | 1 | 1 | 1 | 1 |
| Infections and infestations | 0 | 0 | 1 | 0 |
| Injury, poisoning and procedural complications | 0 | 0 | 1 | 0 |
| Investigations | 1 | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | 1 | 0 | 0 | 0 |
| Nervous system disorders | 2 | 1 | 1 | 0 |
| Renal and urinary disorders | 0 | 0 | 1 | 1 |
| Skin and subcutaneous tissue disorders | 1 | 0 | 1 | 0 |
Collected over 4 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1 | 3/3 (100%) | 0/3 (0%) | 2/3 (66.7%) |
| Dose Level 2 | 2/2 (100%) | 0/2 (0%) | 1/2 (50%) |
| Dose Level 3 | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Level 4 | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Event | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| SeizureNervous system disorders | 0/3 | 0/2 | 1/3 | 0/1 |
| Event | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| General disorders and administration site conditions - Other, specifyGeneral disorders | 1/3 | 0/2 | 2/3 | 1/1 |
| Gastrointestinal disorders - Other, specifyGastrointestinal disorders | 0/3 | 0/2 | 0/3 | 1/1 |
| Urinary frequencyRenal and urinary disorders | 0/3 | 0/2 | 0/3 | 1/1 |
| Urine discolorationRenal and urinary disorders | 0/3 | 0/2 | 0/3 | 1/1 |
| FatigueGeneral disorders | 0/3 | 1/2 | 1/3 | 0/1 |
| HeadacheNervous system disorders | 0/3 | 1/2 | 0/3 | 0/1 |
| SeizureNervous system disorders | 0/3 | 1/2 | 1/3 | 0/1 |
| FallInjury, poisoning and procedural complications | 1/3 | 0/2 | 0/3 | 0/1 |
| Creatinine increasedInvestigations | 1/3 | 0/2 | 0/3 | 0/1 |
| Muscle weakness lower limbMusculoskeletal and connective tissue disorders | 1/3 | 0/2 | 0/3 | 0/1 |
| Age, Continuous(years) | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Total |
|---|---|---|---|---|---|
| Mean | 59.33 ± 9.45 | 68.5 ± 9.19 | 55 ± 14.8 | 65 ± NA | 60.6 ± 10.9 |
| Sex: Female, Male(Participants) | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Total |
|---|---|---|---|---|---|
| Female | 2 | 0 | 1 | 1 | 4 |
| Male | 1 | 2 | 2 | 0 | 5 |
| Race (NIH/OMB)(Participants) | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
| White | 3 | 1 | 2 | 1 | 7 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Total |
|---|---|---|---|---|---|
| United States | 3 | 2 | 3 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Feb 2025, 48 months.
Results were first posted in Oct 2026, 1 year 8 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Aug 2025 → Feb 2025 and completion Aug 2025 → Feb 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
PI Decision
PI Decision
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Verteporfin